AN2 Therapeutics Inc ANTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 03/17/23 EDT
8.85quote price arrow up+0.91 (+11.46%)
Volume
209,464
52 week range
6.88 - 23.58
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.85
  • 52 Week High23.58
  • 52 Week High Date05/16/22
  • 52 Week Low6.88
  • 52 Week Low Date06/30/22

Key Stats

  • Market Cap171.714M
  • Shares Out19.40M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-7.14

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.85
  • 52 Week High23.58
  • 52 Week High Date05/16/22
  • 52 Week Low6.88
  • 52 Week Low Date06/30/22
  • Market Cap171.714M
  • Shares Out19.40M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-7.14

RATIOS/PROFITABILITY

  • EPS (TTM)-1.99
  • P/E (TTM)-4.44
  • Fwd P/E (NTM)-3.01
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AN2 Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic and progressive infectious disease caused by bacteria, mycobacteria. Epetraborole has antimycobacterial activity...
Joseph Zakrzewski
Chairman of the Board, Co-Founder
Eric Easom
President, Chief Executive Officer, Co-Founder, Director
Lucy Day
Chief Financial Officer, Treasurer, Secretary
Address
1800 El Camino Real, Suite D
Menlo Park, CA
94025-3069
United States